Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
about
The regulatory role of DPP4 in atherosclerotic disease.The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarctionAssociation between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Acarbose Accelerates Wound Healing via Akt/eNOS Signaling in db/db Mice.Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options.Incidence of diabetes-related complications in Chinese patients with type 1 diabetes: a population-based longitudinal cohort study in Taiwan.Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms.Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice.Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and highBoth pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus
P2860
Q33805518-5A4FB2CA-A58E-4AEC-9243-4D6B3E4F6201Q33893254-1F363814-D873-4937-B765-099E301B896FQ37228390-197F6DD8-22E2-44A6-A97D-218F9BFB3809Q37620904-5E596E7E-0B6E-45F9-9B38-06A1A2290DDFQ37714714-4E9547B0-8279-4700-A57F-5AC6049C3606Q39245449-4C11E276-B0EF-45C7-8591-ABC07970338FQ40150694-B1043DAC-1843-4280-B26F-8972B1CD6C04Q42379243-F00B98C9-3F92-4027-BD1D-6FB37C661C8DQ43826855-E0801F8A-727D-4C22-9662-5CF302136F3BQ47103078-1A8CE845-6360-429C-BC4A-C9F88A3CB583Q47148482-BA68ADEB-3F1B-48C0-9478-9D81BADA9544Q47156408-E8A38A28-7580-4056-A322-951B4EF7AD87Q47556634-A64F2C3E-6D13-4AC2-8D58-0AEE0185D2E8Q52655639-6A3C1630-DFBF-4D4C-A57E-F98F822F6EB1Q58691957-B359CC24-4E2C-485B-AFE5-EE733D80BF94
P2860
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Risks of cardiovascular diseas ...... ation-wide longitudinal study.
@ast
Risks of cardiovascular diseas ...... ation-wide longitudinal study.
@en
type
label
Risks of cardiovascular diseas ...... ation-wide longitudinal study.
@ast
Risks of cardiovascular diseas ...... ation-wide longitudinal study.
@en
prefLabel
Risks of cardiovascular diseas ...... ation-wide longitudinal study.
@ast
Risks of cardiovascular diseas ...... ation-wide longitudinal study.
@en
P2093
P2860
P1476
Risks of cardiovascular diseas ...... ation-wide longitudinal study.
@en
P2093
Chung-Yi Li
Huang-Tz Ou
Jin-Shang Wu
Kai-Cheng Chang
P2860
P2888
P356
10.1186/S12933-016-0350-4
P407
P577
2016-03-01T00:00:00Z
P6179
1000374984